Associate Professor Will Herrington
Websites
- Medical Research Council Population Health Research Unit at the University of Oxford
-
Medical Research Council-UK
Professor David Kerr Clinician Scientist Award, 2018-2022
-
Kidney Research UK
Professor David Kerr Clinician Scientist Award, 2018-2022
- Health Data Research UK
-
British Heart Foundation
Centre of Research Excellence
- The EMPA-KIDNEY study
- Mexico City Prospective Study
- The SHARP trial
- Cholesterol Treatment Trialists' Collaboration
- The UK-HARP3 trial
- The 3C trial
-
Oxford Kidney Unit
Honorary Consultant Nephrologist
-
Kidney Diseases: Improving Global Outcomes (KDIGO)
Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology
-
Clinical Trial Transformation Initiative
Developing Novel Endpoints Generated by Mobile Technology for Use in Clinical Trials
-
MSc in Global Health Science and Epidemiology
Record Linkage and Bioinformatics Module Lead
Will Herrington
MA, MBBS, MD, FRCP
MRC-Kidney Research UK Professor David Kerr Clinician Scientist
- Associate Professor, Renal Studies Group, MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Univ. of Oxford
- Honorary Consultant Nephrologist, Oxford Kidney Unit
BIOGRAPHY
Will Herrington is a Medical Research Council-Kidney Research UK Professor David Kerr clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’.
He now aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. He is also interested in incorporating more routine healthcare data and mobile technology into large-scale renal epidemiology and streamlined trials.
He co-leads the EMPA-KIDNEY study, a trial testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6000 people with chronic kidney disease with and without diabetes.
He collaborates with the Mexico City Prospective Study, the Cholesterol Treatment Trialists' Collaboration, UK Biobank, China-Kadoorie Biobank, and the Prospective Studies Collaboration. He is module co-lead for the Record Linkage and Bioinformatics module in the department’s MSc in Global Health Science. He has also advised the Kidney Health Initiative, the Clinical Trials Transformation Initiative and was Scientific Co-ordinator for the KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology.